A phase II study of the Cladribine and Rituximab combination therapy for relapsed and refractory indolent B-cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2008
At a glance
- Drugs Cladribine (Primary) ; Rituximab (Primary)
- Indications B cell lymphoma
- Focus Therapeutic Use
- 18 Dec 2008 New trial record.